Bausch + Lomb (BLCO) has put its dry age related macular degeneration program in sharper focus after a constructive FDA meeting clarified the clinical path for its oral candidate BL1243, also known as tonabersat.
At a share price of US$17.34, Bausch + Lomb has logged a 4.58% year to date share price return and a 17.88% total shareholder return over the past year. The recent FDA feedback arrives as momentum softens, with a 3.88% decline over 30 days but a 3.65% gain on a 90 day share price basis.
Look beyond Bausch + Lomb's dry AMD update and compare it with other healthcare names showing solid fundamentals using the curated list of solid balance sheet and fundamentals (25 results).
Bulls point to Bausch + Lomb's clarified dry AMD path and earlier trial data, while bears flag losses and execution risk. Which story does the current valuation lean toward as you weigh today’s US$17.34 share price?
Most Popular Narrative: 56% Undervalued
Bausch + Lomb is tied to a widely followed valuation story that places fair value at $39.23 per share, well above the recent $17.34 close. This frames the dry AMD news against a much larger debate about what the business could be worth over time.
For more than a week following the company’s Annual General Meeting (AGM), shareholders have been left without a single published result, filing, press release, or confirmation of what occurred inside the meeting. This absence of disclosure is not normal, not industry standard, and not aligned with the obligations of a publicly traded company.
See why 5 investors see Bausch + Lomb as 56% undervalued.
Result: Fair Value of $39.23 (UNDERVALUED)
Still, the governance overhang from the AGM silence and the current losses on US$5,324.0m in revenue could both challenge the Bausch + Lomb undervalued narrative.
Find out about the key risks to this Bausch + Lomb narrative.
Next Steps
The split view on Bausch + Lomb is clear, with risks and rewards both on the table. Move quickly, review the data, and ground your decision in the full 3 key rewards and 1 important warning sign
Looking for more Bausch + Lomb sized opportunities?
If you are serious about sharpening your ideas beyond Bausch + Lomb, use the Simply Wall Street Screener to spot opportunities before they move away from you.
- Target potential mispricings by scanning companies that combine strong fundamentals with appealing valuations through the 29 high quality undervalued stocks.
- Build a steadier core in your portfolio by focusing on cash payouts and consistency with the 8 dividend fortresses.
- Reduce unpleasant surprises by focusing on resilient businesses with healthier financial profiles using the 31 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com